GlaxoSmithKline: Multiple Sclerosis trials
The registry lists 13 Multiple Sclerosis studies with GlaxoSmithKline as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 7Phase 2 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy ParticipantsCompletedNCT05131971Phase 1Results posted
- Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple SclerosisCompletedNCT01457924Phase 2Results posted
- Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT00640328Phase 2Results posted
- A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)TerminatedNCT01808482Phase 1
- GSK239512 DDI StudyCompletedNCT01802931Phase 1
- Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple SclerosisTerminatedNCT01435993Phase 1
- [18F]PBR111 and Microglial Activation in Multiple SclerosisTerminatedNCT01428505Phase 2
- NOGO-A in Multiple Sclerosis FTIHTerminatedNCT01424423Phase 1
- GSK2018682 FTIH in Healthy VolunteersCompletedNCT01387217Phase 1
- Firategrast (SB683699) Surface Area Study in Multiple Sclerosis PatientsCompletedNCT00548769Phase 1
- Study Of White Blood Cells In The Cerebrospinal Fluid And Blood Of Patients With Relapsing Forms Of Multiple SclerosisCompletedNCT00469378Phase 2
- Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS)CompletedNCT00395317Phase 2
- Three Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisCompletedNCT00097331Phase 2